| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8580841 | PFIZER | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
Mar, 2030
(5 years from now) | |
| US11091435 | PFIZER | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1P1 receptor-associated disorders |
Jun, 2036
(12 years from now) | |
| US10301262 | PFIZER | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
Jun, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9126932 | PFIZER | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
Jul, 2029
(5 years from now) | |
| US11007175 | PFIZER | Methods of treating conditions related to the S1P1 receptor |
Jan, 2036
(11 years from now) | |
| US10676435 | PFIZER | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders |
Jun, 2036
(12 years from now) | |
Velsipity is owned by Pfizer.
Velsipity contains Etrasimod Arginine.
Velsipity has a total of 6 drug patents out of which 0 drug patents have expired.
Velsipity was authorised for market use on 12 October, 2023.
Velsipity is available in tablet;oral dosage forms.
Velsipity can be used as a method for treating ulcerative colitis by administering estrasimod arginine in an amount equivalent to about 2.0 mg of estrasimod, a method for treating ulcerative colitis by administering a therapeutically effective amount of the form of estrasimod arginine as claimed, a method for treating ulcerative colitis by administering a therapeutically effective amount of estrasimod arginine.
Drug patent challenges can be filed against Velsipity from 13 October, 2027.
The generics of Velsipity are possible to be released after 21 June, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2028 |
Drugs and Companies using ETRASIMOD ARGININE ingredient
NCE-1 date: 13 October, 2027
Market Authorisation Date: 12 October, 2023
Treatment: A method for treating ulcerative colitis by administering a therapeutically effective amount of estrasimod arginine; A method for treating ulcerative colitis by administering estrasimod arginine in an...
Dosage: TABLET;ORAL
VELSIPITY family patents
